Company Filing History:
2 out of 64 
2 out of 44 
Years Active: 2017-2019
Title: Rob Livingston: An Innovator in Anxiolytic Compounds
Introduction
Rob Livingston is a notable inventor based in Cambridge, MA, known for his contributions to the field of pharmaceutical sciences. With a focus on the development of anxiolytic compounds, he holds two patents that showcase his innovative approach to treating central nervous system disorders, particularly anxiety.
Latest Patents
Livingston's latest patents include advancements in crystalline forms of anxiolytic compounds. The first patent details the invention of crystalline forms FUM-P3, FUM-P4, MLA-P3, and MLA-P4, which are part of a unique compound formula aimed at treating anxiety disorders. The methods outlined in this patent emphasize the application of these crystalline forms in pharmaceutical compositions designed to prevent or treat diseases related to the central nervous system.
In his second patent, Livingston presents both amorphous and crystalline forms of the compound known as 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one. This invention also includes relevant methods for utilizing these forms, alongside salts and co-crystals, to address and manage central nervous system diseases.
Career Highlights
Rob Livingston has made significant strides in his career as an inventor while working with leading companies in the pharmaceutical industry. He has been involved with Bionomics Inc. and Ironwood Pharmaceuticals, Inc., where he applied his research expertise to develop innovative solutions for anxiety and related disorders.
Collaborations
Throughout his career, Livingston has collaborated with esteemed colleagues such as Bernard Luke Flynn and Dharam Paul. These partnerships have helped enhance his research and expand the impact of his inventions in the pharmaceutical field.
Conclusion
Rob Livingston continues to be an influential figure in the research and development of anxiolytic compounds. His innovative patents and collaborations with significant companies and talented individuals underscore his commitment to advancing treatments for anxiety disorders. Through continued research, Livingston's work holds promise for improving the lives of those affected by such conditions.